Clinical Scenario

This protocol addresses migraine without aura in patients who have already received triptan (5-HT1B/1D-agonist) monotherapy and did not achieve the primary goal: freedom from pain or meaningful headache reduction within 2 hours. A structured next-line strategy is indicated.

Previous line did not meet target

Prior Therapy & Failure Condition

First-line treatment was triptan monotherapy. The expected endpoint — freedom from pain or significant headache reduction at 2 hours — was not achieved, which triggers escalation to this next-line protocol.

Treatment Approach (Partial Overview)

The next step moves beyond triptan monotherapy to a combination strategy — pairing a triptan with a long-acting NSAID. This combination approach has been shown to outperform either agent alone and targets both acute pain relief and the prevention of headache recurrence. The complete regimen, including agent selection and full clinical guidance, is available in the structured protocol.

Treatment Goals

Freedom from pain or significant reduction in headache intensity within 2 hours of administration
Prevention of recurrence of the migraine attack

References

The initial combination of a triptan with a long-acting NSAID (such as naproxen) is more effective than the individual components and can in part prevent the recurrence of migraine attacks.
In unsatisfactory effectiveness of a triptan, the triptan may be combined with a rapid-acting NSAID.
The combination of triptans with naproxen is more effective than monotherapy.
Compared to placebo, the numbers needed to treat (NNT) was 4.9, when the initial headache was moderate or severe.

DOI: 10.1177/2514183X1882337

View source ↗

Migraine without Aura When Triptan Therapy Did Not Achieve Adequate Pain Relief

References